Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

Codeine containing preparations lose their OTC status

It will get more difficult to procure Codeine based pain killers, cough syrups etc. from the local pharmacists from now on. There have been new restrictions over codeine based drugs like Nurofen Plus, Panadeine and Mersyndol which were initially sold over the counter but lost this OTC status with effect from May 1st 2010. The National Drugs and Poisons Schedule Committee formulated the changes during meetings in June and October last year.

2 May 2010

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

Healthy people with high blood pressure who excrete a slight excess of protein in the urine raise their risk of developing kidney and heart complications. According to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN), more attention should focus on the potential health effects of urinary protein excretion in individuals with high blood pressure (hypertension).

30 Apr 2010

Hormone mimic Octreotide promising for treatment of polycystic liver disease caused by ADPKD: Study

A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

30 Apr 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Factors of hormone metabolism may make African-Americans more susceptible: Study

High blood pressure also called hypertension is a major health problem that when left untreated can lead to heart disease, stroke and kidney failure. African Americans are more likely to develop high blood pressure and develop it earlier in life than Caucasians. But the reasons for the heightened risk in African Americans still remained largely unknown, although new evidence may provide some insight.

26 Apr 2010

Study reveals new marker for predicting patients requiring blood transfusion in ICU

Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.

24 Apr 2010

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.

23 Apr 2010

FDA provides guidance to help caregivers, patients safely use complex medical devices in home

The U.S. Food and Drug Administration today announced a new initiative to ensure that caregivers and patients safely use complex medical devices in the home.

21 Apr 2010

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Type 1 diabetes is the most common cause of diabetes in children, although it may occur at any age. Also called juvenile diabetes, this pathology usually results from autoimmune destruction of insulin-producing cells of the pancreas.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Artificial pancreas system succeeds in maintaining near-normal glucose levels

An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston University.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

Older patients more likely to die in hospital following implantation of defibrillators: Report

Older patients may be more likely to die in the hospital following the implantation of defibrillators or pacemakers, according to a report in the April 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Renal specialist says Dr Patel’s patient was too frail for surgery

In the ongoing trial of Dr Jayant Patel, Dr Peter Miach, a renal specialist, gave evidence before the Supreme Court in Brisbane. Dr Miach said the patient James Phillips had too many other problems and he would not have recommended surgery for him in his frail state.

12 Apr 2010

Renal Failure News and Research

Further Reading

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Codeine containing preparations lose their OTC status

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

Hormone mimic Octreotide promising for treatment of polycystic liver disease caused by ADPKD: Study

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Factors of hormone metabolism may make African-Americans more susceptible: Study

Study reveals new marker for predicting patients requiring blood transfusion in ICU

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

FDA provides guidance to help caregivers, patients safely use complex medical devices in home

NanoBio to develop intranasal vaccine for HBV

Diabetic mice generate new insulin-producing cells following extreme cell destruction

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Artificial pancreas system succeeds in maintaining near-normal glucose levels

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

XOMA expands anti-inflammatory antibody intellectual property portfolio

Older patients more likely to die in hospital following implantation of defibrillators: Report

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Gilead Sciences doses first patient in Quad Phase III clinical program

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Renal specialist says Dr Patel’s patient was too frail for surgery

Free guide - Everything about renal proximal tubule cells eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News